WB, IP
H
Endogenous
92
Rabbit IgG
#Q86VP1
8887
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human TAX1BP1 protein.
Background
Tax1-binding protein (TAX1BP) 1 is an essential regulator of innate immunity and was originally identified in a yeast two-hybrid screen as a human T-lymphotropic virus Type 1 (HTLV-1) Tax1-binding protein and named TXBP151 (1-3). Independently, TAX1BP1 was discovered in yeast two-hybrid screens that sought to identify novel binding partners of A20 (4) and TRAF6, where it was named T6BP (5). Two human TAX1BP1 transcripts encoding modular proteins of 747 and 789 amino acids have been identified (4). The N-terminal region of TAX1BP1 possesses a SKIP carboxyl homology (SKITCH) domain and a 14-3-3 binding motif. The central region of TAX1BP1 harbors coiled-coil structures and helix-loop-helix regions that are thought to promote the formation of TAX1BP1 homodimers (5). The TAX1BP1 C-terminal region posesses zinc finger domains that function as novel ubiquitin-binding domains and allow for complex formation with K63-ubiquitinated RIP1 and TRAF6 (6) as well as the E3 ubiquitin ligase ITCH (7). One of the major physiologic roles of TAX1BP1 is to serve as an essential component of a negative feedback loop aimed at restraining canonical NF-κB-mediated proinflammatory signaling cascades initiated by TNF and IL-1. It is likely that TAX1BP1 functions as a ubiquitin-binding adaptor protein that inducibly recruits A20 to a complex consisting, in part, of K63-ubiquitinated TRAF6, RIP1, and their cognate E2 conjugating enzyme, thus allowing for A20-mediated ubiquitin-editing and termination of NF-κB signaling (6,8,9). A recent report identified IKKα as a novel regulator of TAX1BP1 function and demonstrated that IKKα-dependent phosphorylation of TAX1BP1 at Ser593 and Ser624 in response to TNF and IL-1 is critical for its ability to orchestrate formation of the A20 ubiquitin-editing complex involved in termination of NF-κB signaling (10).
- Chin, K.T. et al. (2007) Cancer Res 67, 1072-81.
- Wu, K. et al. (2004) J Biol Chem 279, 495-508.
- Gachon, F. et al. (1998) J Virol 72, 8332-7.
- De Valck, D. et al. (1999) Oncogene 18, 4182-90.
- Ling, L. and Goeddel, D.V. (2000) Proc Natl Acad Sci USA 97, 9567-72.
- Iha, H. et al. (2008) EMBO J 27, 629-41.
- Shembade, N. et al. (2009) EMBO J 28, 513-22.
- Shembade, N. et al. (2010) Science 327, 1135-9.
- Shembade, N. et al. (2007) EMBO J 26, 3910-22.
- Shembade, N. et al. (2011) Nat Immunol 12, 834-43.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.